Roman Kasianov
Covers AI in drug discovery, digital pathology, and translational R&D, editor of "Where Tech Meets Bio"; oversees company profiles, partnerships, and core operations at BiopharmaTrend.
Recent articles from Roman
OpenAI Backs Ultrasound-Based Brain-Computer Interface Startup With $252M Seed Round
Merge Labs has emerged from stealth with $252 million in funding to develop non-implantable brain–computer interfaces that use ultrasound and molecular approaches rather than electrodes. The company is cofounded by Sam Altman and is positioned at the intersection of neurotechnology, …
Insilico Deploys its Chemistry Foundation Model on Microsoft Discovery Platform
Insilico Medicine reported the deployment of its Nach01 multimodal foundation model on Microsoft Discovery, Microsoft’s Azure-based platform for AI-driven research and development. The demonstration illustrates how third-party foundation models can be orchestrated within a single enterprise environment to support end-to-end …
Novo Nordisk Foundation Commits €736M to Scale European Life Sciences
The Novo Nordisk Foundation has committed up to €736 million (~$856 million) to Copenhagen-based BioInnovation Institute in a nine-year funding program aimed at expanding early-stage life sciences and deep tech activity across Europe. The capital is earmarked to increase the …
Converge Bio Raises $25M for Generative AI Systems in Antibody and Protein Design
Converge Bio, a Boston- and Tel Aviv-based startup developing generative AI systems for drug discovery, has raised a $25 million oversubscribed Series A round led by Bessemer Venture Partners, with participation from TLV Partners, Saras Capital, Vintage Investment Partners, and …
NVIDIA and Lilly Launch $1B AI Co-Innovation Hub for Drug Discovery in South San Francisco
Eli Lilly and NVIDIA announced at the January 12, 2026 J.P. Morgan Healthcare Conference in San Francisco that they are creating a new AI co-innovation lab in South San Francisco, with the companies planning to invest up to $1 billion …
Owkin Partners with NVIDIA, Rolls Out Multimodal Agent Platform Integrated with Claude
Owkin has entered its first collaboration with NVIDIA to advance the development of its biological large reasoning model, OwkinZero, using NVIDIA’s open AI infrastructure and reinforcement learning toolkit.
Announced today at JPM Healthcare Conference 2026 in San-Francisco, the partnership …
After IPO, AI Drug Developer Insilico Medicine Advances Gut-Restricted PHD Inhibitor Into Phase II IBD Trial
Insilico Medicine reported first patient first dose in a Phase IIa clinical trial of its gut-restricted PHD inhibitor ISM5411, now assigned the generic name garutadustat.
The milestone moves the AI-designed program into mid-stage clinical testing in ulcerative colitis, …
Manas AI and Schrödinger Partner on Deep Integration of Physics-Based Modeling into AI Drug Discovery Platform
LinkedIn founder Reid Hoffman and Siddhartha Mukherjee’s Manas AI has entered a multi-year strategic agreement with Schrödinger, securing privileged access to its physics-based molecular modeling platform along with direct engagement from internal technical teams.
Announced during the 2026 J.P. …
MIT Team Behind Boltz Launches With $28M, Pfizer Collaboration, and Three Guarantees
Boltz has launched as a public benefit corporation and paired the company formation with three operational announcements: a $28 million seed financing, a multi-year collaboration with Pfizer, and a preview release of its hosted platform with two initial discovery …
Servier Signs €1B-Plus Multi-Target AI Drug Discovery Partnership With Iktos
Iktos and Servier have entered a multi-year, multi-target research collaboration under which Iktos will apply its AI-driven molecular design and automated synthesis platform to discover small-molecule drug candidates, while Servier will lead biological evaluation and downstream development. The agreement spans …